Sugi Predict

Sugi Predict / Compounds / SCHEMBL372669

SCHEMBL372669

SCHEMBL372669

COc1cc2c(Oc3ccc(NC(=O)C(=O)NCCc4ccc(F)cc4)cc3F)ccnc2cc1OCC1CCNCC1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 15/20 0.62
▸ AXL P30530 4/20 0.57
▸ KDR P35968 3/20 0.57
▸ FLT3 P36888 3/20 0.55
▸ HDAC2 Q92769 2/20 0.53
▸ HDAC8 Q9BY41 2/20 0.53
▸ HDAC6 Q9UBN7 2/20 0.53
▸ RET P07949 1/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ KIT P10721 1/20 0.53
▸ PDGFRA P16234 1/20 0.52
▸ HDAC10 Q969S8 1/20 0.52
▸ HDAC11 Q96DB2 1/20 0.52
▸ MERTK Q12866 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371591 0.95 MET (0.63) METAXLKDRFLT3
SCHEMBL372393 0.95 MET (0.61) METAXLKDRFLT3PDGFRB
SCHEMBL371865 0.95 MET (0.61) METAXLKDRFLT3
SCHEMBL371555 0.95 MET (0.63) METAXLKDRFLT3
SCHEMBL371633 0.94 MET (0.61) METAXLKDRFLT3HDAC2
SCHEMBL371816 0.94 MET (0.61) METAXLKDRFLT3
SCHEMBL371784 0.94 MET (0.62) METAXLKDRFLT3
SCHEMBL371680 0.94 MET (0.67) METKDRFLT3
SCHEMBL371553 0.94 MET (0.62) METAXLKDRFLT3PDGFRA
SCHEMBL29693566 0.94 MET (0.67) METKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20140155378-A9 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2014-06-05 — — US claimed
US-20130252940-A1 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2013-09-26 — — US claimed
US-8476298-B2 c-Met modulators and method of use EXELIXIS, INC. (US) 2013-07-02 — — US claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20140155378-A9 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20130252940-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.